Literature DB >> 17164395

Fentanyl HCl patient-controlled iontophoretic transdermal system for the management of acute postoperative pain.

Stacey Mayes1, Marcus Ferrone.   

Abstract

OBJECTIVE: To summarize the pharmaceutics, pharmacokinetics, development, and clinical application of IONSYS, the fentanyl HCl patient-controlled iontophoretic transdermal system for the management of acute postoperative pain. DATA SOURCES: Clinical literature including both primary sources and review articles was accessed through a search of the MEDLINE databases (1980-October 2006). Key search terms included cutaneous analgesia, fentanyl, IONSYS, opioid, postoperative pain, and patient-controlled analgesia (PCA). Additional clinical trial and drug data were supplied by the manufacturer, the ALZA Corporation. STUDY SELECTION AND DATA EXTRACTION: Review articles, abstracts, and clinical studies related to patient-controlled iontophoretic transdermal fentanyl and postoperative pain management were analyzed. An evaluation of the research exploring IONSYS for the management of acute postoperative pain was conducted. Relevant information was then selected and is provided in this article. DATA SYNTHESIS: IONSYS is the first iontophoretic transdermal drug delivery system that utilizes low-level electrical energy to actively transport ionized fentanyl HCl through intact skin. Research has revealed that use of IONSYS for patients with acute postoperative pain is safe, effective, and well tolerated. Phase I-III trials have demonstrated an appropriate dosing range leading to effective analgesia, with minimal adverse effects. The analgesia provided by this system was found to be superior to that of analgesia placebo and equivalent to that of an intravenous morphine PCA.
CONCLUSIONS: Data from clinical trials indicated that IONSYS is successful in controlling acute postoperative pain that circumvents the limitations of intravenous patient-controlled analgesia. The use of this system may serve as an alternative modality for the management of acute pain without increasing such adverse effects as bleeding, intravenous catheter infiltration, or manual pump malfunction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17164395     DOI: 10.1345/aph.1H135

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  19 in total

1.  "I am in pain!"-a case report of illicit use of transdermal fentanyl patches.

Authors:  Wei Guan; Ronald Schneider; James Patterson
Journal:  Prim Care Companion CNS Disord       Date:  2011

Review 2.  MicroRNAs in opioid pharmacology.

Authors:  Cheol Kyu Hwang; Yadav Wagley; Ping-Yee Law; Li-Na Wei; Horace H Loh
Journal:  J Neuroimmune Pharmacol       Date:  2011-11-09       Impact factor: 4.147

3.  Development and characterisation of novel fentanyl-delta opioid receptor antagonist based bivalent ligands.

Authors:  M F Bird; R S Vardanyan; V J Hruby; G Calò; R Guerrini; S Salvadori; C Trapella; J McDonald; D J Rowbotham; D G Lambert
Journal:  Br J Anaesth       Date:  2015-02-13       Impact factor: 9.166

Review 4.  Transdermal drug delivery.

Authors:  Mark R Prausnitz; Robert Langer
Journal:  Nat Biotechnol       Date:  2008-11       Impact factor: 54.908

5.  [The postoperative pain therapy].

Authors:  René Pschowski; Johann Motsch
Journal:  Wien Med Wochenschr       Date:  2008

Review 6.  An overview of clinical and commercial impact of drug delivery systems.

Authors:  Aaron C Anselmo; Samir Mitragotri
Journal:  J Control Release       Date:  2014-04-18       Impact factor: 9.776

7.  Polymeric nanoparticle system to target activated microglia/macrophages in spinal cord injury.

Authors:  Simonetta Papa; Raffaele Ferrari; Massimiliano De Paola; Filippo Rossi; Alessandro Mariani; Ilaria Caron; Eliana Sammali; Marco Peviani; Valentina Dell'Oro; Claudio Colombo; Massimo Morbidelli; Gianluigi Forloni; Giuseppe Perale; Davide Moscatelli; Pietro Veglianese
Journal:  J Control Release       Date:  2013-11-10       Impact factor: 9.776

8.  MicroRNA 339 down-regulates μ-opioid receptor at the post-transcriptional level in response to opioid treatment.

Authors:  Qifang Wu; Cheol Kyu Hwang; Hui Zheng; Yadav Wagley; Hong-Yiou Lin; Do Kyung Kim; Ping-Yee Law; Horace H Loh; Li-Na Wei
Journal:  FASEB J       Date:  2012-10-19       Impact factor: 5.191

Review 9.  Pediatric palliative care: use of opioids for the management of pain.

Authors:  Boris Zernikow; Erik Michel; Finella Craig; Brian J Anderson
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

10.  Topical preparations for pain relief: efficacy and patient adherence.

Authors:  Liliana L Jorge; Caroline C Feres; Vitor Ep Teles
Journal:  J Pain Res       Date:  2010-12-20       Impact factor: 3.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.